Medindia

X

Expert Explains Failure of First Inhaled Insulin Product

by VR Sreeraman on  September 25, 2009 at 11:56 AM Diabetes News   - G J E 4
 Expert Explains Failure of First Inhaled Insulin Product
An Indian-origin expert at the University of Colorado Denver has shed light on why an inhaled insulin product turned out to be a commercial failure.
Advertisement

Dr. Satish K. Garg, a professor of Medicine and Pediatrics at the University of Colorado Denver, says that the results of a 2-year Phase 3 trial conducted in 385 patients suggest that AIR inhaled insulin was inferior to SC insulin in its ability to maintain optimal blood glucose levels over time, based on measurements of glycosylated hemoglobin (HbA1c).

Advertisement
Similarly, another study on 500 patients with type 1 diabetes showed inferiority of AIR in a 6-month trial.

"The question now remains whether this route of delivering insulin has been exhausted or if it still remains to be explored," writes Dr. Satish Garg, who is also the Editor-in-Chief of Diabetes Technology and Therapeutics, and William Kelly, from the University of Colorado Denver.

An editorial titled 'Insulin Delivery via Lungs-Is It Still Possible?' says that a company called MannKind Corporation has recently filed a New Drug Application with the Food and Drug Administration (FDA) for Technosphere Insulin.

It offers faster onset of action with lower postprandial blood glucose excursions especially in the first two hours and is weight neutral, according to the Editorial.

Source: ANI
SRM
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All